title: The role of the ubiquitin proteasome system in lymphoma.
abstract: The ubiquitin-proteasome system (UPS) maintains the integrity of cellular processes by controlling protein degradation pathways. The role of the UPS in proliferation, cell cycle, differentiation, DNA repair, protein folding, and apoptosis is well documented, and a wide range of protein activities in these signaling pathways can be manipulated by UPS inhibitors, which include many anti-cancer agents. Naturally occurring and synthetic drugs designed to target the UPS are currently used for hematological cancers, including lymphoma. These drugs largely interfere with the E1 and E2 regions of the 26S proteasome, blocking proteasomal activity and promoting apoptosis by enhancing activities of the extrinsic (death receptors, Trail, Fas) and intrinsic (caspases, Bax, Bcl2, p53, nuclear factor-kappa B, p27) cell death programs. This review focuses on recent clinical developments concerning UPS inhibitors, signaling pathways that are affected by down-regulation of UPS activities, and apoptotic mechanisms promoted by drugs in this class that are used to treat lymphoma.
authors.affiliation: John Theurer Cancer Center, Hackensack University Medical Center, NJ 07601, United States. ksuh@HackensackUMC.org
authors.forename: K Stephen
authors.initials: KS
authors.lastname: Suh
authors.forename: Takemi
authors.initials: T
authors.lastname: Tanaka
authors.forename: Sreeja
authors.initials: S
authors.lastname: Sarojini
authors.forename: Ginah
authors.initials: G
authors.lastname: Nightingale
authors.forename: Rajendra
authors.initials: R
authors.lastname: Gharbaran
authors.forename: Andrew
authors.initials: A
authors.lastname: Pecora
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D025801:Ubiquitin / Q000378:metabolism*; D056811:Unfolded Protein Response / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D061988:Proteasome Inhibitors; D025801:Ubiquitin; D046988:Proteasome Endopeptidase Complex
keywords: Bortezomib; CEP-18770; Carfilzomib; Clinical trials-UPS inhibitors; Lymphoma; Marizomib; Ubiquitin proteasome system